CME Meeting Series
Dear Colleagues:
The “Anti-VEGF Revolution” continues to shape the management of retinal disease. The use of anti-VEGF agents remains the core therapy for the treatment of neovascular age-related macular degeneration. However, many questions remain for the retinal practitioner: Which drug? Which treatment strategy? How to best use OCT as a clinical decision-making tool? What constitutes treatment failure?
New research has established that anti-VEGF treatment can also be used effectively in the management of edema associated with retinal vein occlusion and diabetic retinopathy. This paradigm shift offers new benefits to more patients while raising new questions for clinicians about how best to manage patients.
I invite you to participate in the special half-day continuing medical education program, “New Developments in Retinal Pharmacotherapy 2013,” which will address these important and vexing questions.
The course is specifically directed to experienced vitreoretinal specialists. We have recruited a nationally recognized faculty to present the latest information and to address the most important controversies that we face in 2013.
The course will be both fast-paced and interactive, with special sections reserved for case presentations and audience participation.
I hope you can join us for this program.
With best regards,
Carmen A. Puliafito, MD, MBA
Course Chair
Course Chair
Carmen A. Puliafito, MD, MBA
Dean, Keck School of Medicine
Professor of Ophthalmology and Health Management
May S. and John Hooval Dean’s Chair in Medicine
University of Southern California
Los Angeles, CA
Co-Chairs
Peter K. Kaiser, MD
Quan Dong Nguyen, MD, MSc
Philip J. Rosenfeld, MD, PhD
Michael W. Stewart, MD